Current clinical success rates of adenoviral vector ( Adv ) -based gene therapy of squamous cell carcinoma ( SCC ) of the head and neck remain unsatisfactory. A major problem with this approach is thought to be related to low Adv transduction efficiency due to weak expression of the adenovirus receptor, coxsackie -adenovirus receptor ( CAR ), in SCC. To improve the limited infectivity of Adv in oral SCC, we constructed mutated Adv incorporating the integrin -binding motif, RGD, in the HI loop of the fiber knob. The mutated Adv infected target cells through integrins commonly expressed in oral SCC. LacZ marker gene expression after infection with this mutated Adv ( Adv -F / RGD ) in oral SCC cell lines that showed reduced expression of CAR was approximately 5 -10 times higher than that obtained with the parental Adv containing wild -type fiber knob ( Adv -F / wt ). In an in vitro study, transduction of oral cancer cell lines with Adv -F / RGD expressing human IL -2 ( AxCAhIL2 -F / RGD ) resulted in greater production of cytokine than AxCAhIL2 -F / wt infection. In an in vivo therapeutic xenograft model of oral SCC in nude mice, AxCAhIL2 -F / RGD demonstrated antitumor effects superior to those of AxCAhIL2 -F / wt. These data suggest that exploitation of genetically altered adenovirus vectors with integrin -binding motifs may offer significant improvements in oral SCC gene therapy.
S quamous cell carcinoma of the head and neck (HNSCC ) afflicts an estimated 500,000 patients annually worldwide. 1 Localized HNSCC is treated by surgery, radiotherapy, radiotherapy plus surgery, or radiotherapy plus chemotherapy. Surgical resection frequently results in significant cosmetic deformity, as well as functional deficits in speech and swallowing. Radiation and chemotherapy are also not innocuous, being accompanied by substantial morbidity including mandibular and laryngeal cartilage radionecrosis, tissue fibrosis, mucosal atrophy, and xerostomia, as well as gastrointestinal, bone marrow, and renal toxicity. 2 Despite ongoing advances in surgery, radiation, and chemotherapeutic strategies, 5-year survival rate remains at 50% overall. In advanced disease (stages III and IV ), the 2 -year survival rate drops to as low as 30%. 1, 3 Because of the poor outcome in advanced HNSCC, new treatment strategies are urgently required. One promising approach currently being investigated is based on gene therapy. Unlike in some carcinomas, direct gene transfer to the primary tumor as well as microscopic residual carcinoma may not be too technically demanding in oral cancer. Because most treatment failures in HNSCC tend to be locoregional, only 10 -15% of patients die solely from distant metastasis. HNSCC patients may, therefore, be ideal candidates for direct gene transfer to persistent or recurrent disease. Thus, it is anticipated that development of local gene therapy would be particularly useful in oral cancer.
Recently, gene therapy has shown promise in preclinical studies as a novel molecular treatment for malignant tumors including oral SCC. Multiple gene transfer strategies involving the introduction of foreign genes that directly kill tumor cells 4, 5 restore a defective tumor-suppressor gene and induce apoptosis, 6 or those that enhance immune responses 7 are presently under investigation for HNSCC. Among the wellstudied cloned genes available for this purpose, the application of herpes simplex virus -tk, 4,8 p53, 9 -11 p16 INK4A , 12 and IL-2 7 has been reported in preclinical investigations and selected clinical trials in HNSCC.
The effective administration of therapeutic genes to tumor cell targets requires an efficient delivery vehicle. While it is accepted that of the available systems, adenoviral vectors ( Advs ), possess superior levels of in vivo gene transfer capability, their present level of efficiency may nonetheless be suboptimal for HNSCC gene therapy. 5 In several clinical trials involving in vivo gene delivery, a relative resistance of target tissues to adenoviral infection has been reported. to resistance to adenovirus -mediated gene transfer. 16, 17 Thus, to treat oral SCC by gene therapy, the development of vectors with higher transduction efficiency and greater specificity is required.
There are several possible strategies to enhance the efficiency of Adv gene transfer. The simplest approach is to use higher MOIs to achieve higher transduction rates. However, use of a higher dose leads to more problems with possible adverse effects, such as allergic immune reactions, or reactions to toxic Adv components such as hexon and penton. Another approach is to create genetically modified Adv, which converts tropism from CAR to other molecules. Because initial recognition and binding by adenovirus particles are achieved by means of interactions between the viral fiber protein and its receptor on the target cell, 18, 19 the fiber protein is a good target for modification of Adv tropism. Several reports have indicated that fiber protein mutations result in viruses with altered tropism, allowing more specific gene transfer to target cells or tissues. One example is an Adv mutant containing a modified fiber in which an RGD -4C peptide 20 has been inserted at the C -terminus 21 or into the HI loop of the fiber knob domain. 16, 22, 23 This enhances Adv -mediated gene transduction to CAR -negative cells through the binding of the RGD peptide to integrins on the targets.
In the present study, we have generated a fiber mutant Adv with an RGD -containing peptide at the HI loop of the fiber knob domain ( Adv -F /RGD ) for transduction of the LacZ marker gene or human IL -2 gene as a representative therapeutic cytokine gene. Subsequently, we investigated whether Adv -F/ RGD can improve transduction efficiency into oral SCC cells expressing low levels of CAR and whether Adv -F/ RGD carrying the human IL -2 gene can exert antitumor effects in an oral SCC xenograft model.
Materials and methods

Cell lines
The HeLa and 293 cells were obtained from the American Type Culture Collection (ATCC; Rockville, MD ). Human oral cancer cell lines HSC2 ( JCRB0622 ) and HSC3 ( JCRB0623) were purchased from the Human Science Research Resources Bank (HSRRB; Osaka, Japan ). The OSC70 line was established in our department from a welldifferentiated SCC of the tongue from a 61 -year-old male.
All cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM; Sigma, St. Louis, MO ) supplemented with 10% fetal bovine serum (FBS ), 2 mM glutamine, penicillin (100 IU /mL ), and streptomycin (100 g/mL ).
Normal oral mucosa was obtained from a healthy adult volunteer in accordance with the ethical code in place in this institute. Tissue (dimensions were about 5Â7 mm ) was rinsed twice in Hanks' balanced salt solutions containing penicillin (100 IU /mL ) and streptomycin ( 100 g /mL ) and cut into small pieces (2Â2 mm ). Normal oral mucosa was cultured in DMEM supplemented with 20% FBS, 2 mM glutamine, penicillin (100 IU /mL ), and streptomycin ( 100 g/ mL ). Cells were incubated at 378C in a 5% CO 2 / 95% air environment.
Animals
Six -week -old female BALB/ cAnNCjr -nu /nu mice were purchased from Charles River Japanese (Yokohama, Japan ). All animals were fed ad libitum, and received humane care in compliance with the institution's guidelines for maintenance and use of laboratory animals in research. All of the experimental protocols involving live animals were reviewed and approved by the Animal Experimentation Committee of Sapporo Medical University.
HSC2 tumor xenografts were established by subcutaneous injection of 5Â10 6 cells into the flank of 6 -week -old female BALB /cANNCjr-nu/ nu mice. On reaching 60-100 mm 3 , the tumor nodules were injected, through a single needle pass, with a dose of 7.5Â10 8 particles of AxCAhIL2-F/ wt or AxCAhIL2 -F /RGD in 50 L of phosphate -buffered saline (PBS ) (six mice per group ). Bidimensional tumor measurements were taken every 3 days with calipers, and the tumor volume was calculated using the simplified formula for a rotational ellipsoid: 0.4 Â length 2 Â width. Animals were followed for 60 days, until the tumor burden in some of the control groups became excessive, and the mice were sacrificed. Statistical analysis was performed using Mann -Whitney analysis with Bonferroni's multiple comparison, and P <.017 was considered to be statistically significant.
For histochemical analysis, mice were euthanized 7 days after the start of treatment, and subcutaneous tumors were stained with hematoxylin -eosin.
Construction and purification of recombinant fiber -modified Adv
Here we cite the reported nucleotide numbers ( nt ) in the wild -type human Adv type 5 ( Ad5 ) genome ( GenBank M73260) to define the position of the restriction enzyme site. An Ad5 mutant with an E3 deletion ( designated E3 ), lacking 1879 bp from nt 28592 to 30470 ( Ad5dlx ), was used for vector construction. A DNA sequence encoding the F / RGD mutant was synthesized by PCR using the template pSKII +nbK20 24 with primers 931 and 1162, or 1161 and 1064, of which the sequences are as follows:
The $750 -bp PCR product from 931 and 1162 was digested with HindIII / SacII. The $350 -bp PCR product from 1161 and 1064 was digested with SacII / MunI.
Each digested PCR product was subcloned into the HindIII / MunI sites of pSKII +nbK20 by three -part ligation, resultingin pSKII +F /RGD, the sequence of which was confirmed by DNA sequencing. The MulI sites correspond to nt 32825 of the repeated Ad5 DNA sequence (M73260), which occurs just 3 0 to the fiber-coding region. A BstBI linker ( pdGCTTCGAAGC ) was inserted into the blunted SacII Cancer Gene Therapy Modified adenovirus for oral cancer H Dehari et al site of pSKII+ 6.7R -K20, 24 and a EcoRI /BstBI fragment from the resulting plasmid was subcloned into the EcoRI/ ClaI site of pWE15 (Clontech, Becton Dickinson, San Jose, CA ), resulting in pWE6.7R -F /K20.
The XbaI/KpnI fragment of pWE6.7R -F / K20 was replaced with the XbaI/KpnI fragment of pSKII+ F /RGD, resulting in pWE6.7R -F / RGD. pAxKM was generated by subcloning the blunted BamHI fragment of pUC -4K ( Amersham Pharmacia Biotech, Piscataway, NJ ) into the SwaI site pAx -cw. 25 The 25 -kbp EcoRI fragment of pAxKM including Ad5 genomic DNA was cloned into the EcoRI site of the pWE6.7R -F/ RGD cosmid. The predicted amino acid sequence of the F /RGD mutant is as follows: T 546 CDCRGDCFCP 547 , where the RGD -4C amino acid sequence is inserted into the HI loop of the fiber knob of the original Ad5 fiber between amino acid residues 546 and 547. To eliminate the AseI site in the LacZ expression cassette of pCAZ2, 24 the blunted AseI-digested fragment of pCAZ3 was cloned into the blunted BglII /SalI sites of pCI Mammalian Expression Vector (Promega, Palo Alto, CA ), resulting in pCAZ3. PAxCAZ3 was constructed by ligation of the BglII /BamHI /blunted fragment of pCAZ3 into the SwaI site of pAc -cw.
Recombinant Adv was constructed essentially according to the procedure described previously. 24, 25 A LacZ -expressing adenovirus was generated by transfection of 293 cells with the pAxCAZ3 cosmid DNA, together with ClaI/ EcoT221 -digested Ad5 genomic DNA -TPC. On the other hand, the F /RGD fiber mutant adenovirus, AxCAZ3-F/ RGD, was generated by transfection of 293 cells with pWEAxKM -F /RGD cosmid DNA, which had been digested with ClaI and PacI, together with the EcoRI/ AseI -digested DNA -TPC of AxCAZ3. Likewise, EcoRIand AseI -digested Ad5 genomic DNA -TPC was cotransfected with pWEAxKM -F /RGD.
Subsequently, DNA -TPC from the resultant Ad5 -F /RGD was digested with ClaI and EcoT221, and was cotransfected with the L -CAhIL2 plasmid 24 to generate the fiber mutant Adv expressing human IL -2.
Advs expressing the human IL-2 gene under the control of the CAG promoter ( AxCAhIL2-F/ wt, AxCAhIL2-F/ RGD ) were used for therapeutic experiments in the mouse xenograft model.
The resulting recombinant adenoviruses were propagated within 293 cells, and purified by CsCl equilibrium centrifugation. Propagated virus were dialyzed against 10 mM PBS, 10% glycerol, and stocked at À 808C until use. Determination of biological virus titer was performed as described previously 25 and by assessing adenoviral particle number, calculated by optical density at 260 nm (OD 260 ). 26, 27 Any contamination with virus containing E1 and /or wild -type fiber was not detected by PCR in virus preparations ( data not shown ). Particle numbers and infectious titers of the Adv preparations are shown in Table 1 .
Expression of CAR and integrins on oral SCC cell lines
Mouse anti -CAR monoclonal antibody, RmcB, prepared as ascites fluid, was kindly provided by Dr Jeffrey Bergelson ( the Children's Hospital of Philadelphia, Philadelphia, PA ). The anti -aVb3 mAb LM609, the anti -avb5 mAb P1F6, the anti-a2b1 mAb BHA2.1, and the anti -a3b1 mAb MAB1992 were purchased from Chemicon International (Temecula, CA ). Control mouse IgG and FITC -conjugated antimouse IgG were purchased from Sigma and Dako Japan ( Kyoto, Japan ), respectively.
Cultured cells were harvested with EDTA solution ( 0.02% ) (Sigma) for 15 minutes. Detached cells were centrifuged and resuspended in PBS containing 1% bovine serum albumin (BSA ) and 0.1% sodium azide ( 1% BSA / PBS ) at a concentration of 10 5 cells/mL. The cells were then incubated with RmcB (1:1000 dilution ), or 25 g/mL anti-integrin antibodies ( M609, P1F6, BHA2.1, MAB1992) for 1 hour on ice. Subsequently, the cells were washed and incubated with FITC -conjugated rabbit antimouse IgG ( Dako ) for 30 minutes on ice and in the dark. After washing in 1% BSA / PBS, the cells were resuspended in 500 L of 1% BSA /PBS. Analysis was performed on a FACS caliber ( Becton Dickinson, San Jose, CA ).
Detection of transgene expression in cells transduced by Adv
Adv infection was carried out according to the following method: HeLa, HSC2, HSC3, and OSC70 cells were plated 4 cells/ well in the presence of 500 L of culture media 1 day before Adv infection. Cells were infected with 200 L of virus suspension containing AxCAZ3 -F /wt or AxCAZ3-F /RGD ( 100-30,000 particles /cell ) at 378C in 5% CO 2 for 1 hour. After infection, the cells were washed with PBS (pH 7.4 ), and then supplemented with 500 L of culture media. The transduction efficiency of Adv with wild -type fiber and Adv with F /RGD fiber was compared by infecting oral cancer cell lines and primary cultured cells of normal oral mucosa with AxCAZ3-F/ wt and AxCAZ3-F/ RGD for 24 -hour LacZ activity measured by a b -gal reporter gene assay (Roche Molecular Biochemicals, Indianapolis, IN ), and 48-hour X -gal (5 -bromo-4-chloro-3-indoyl -b -Dgalactopyranoside ) staining was performed as previously described. 28 Statistical analysis was performed using MannWhitney analysis, and P < .05 was considered to be statistically significant.
Detection of human IL -2
For in vitro human IL -2 production from oral cancer cell lines transduced with AxCAhIL2 -F /wt and AxCAhIL2 -F / RGD, HSC2 and HSC3 cells were plated in 24 -well plates in triplicate at 10 4 cells/well 12 hours prior to adenovirus infection. Cells were infected with either AxCAhIL2-F/ wt or AxCAhIL2-F/ RGD and incubated for 48 hours. Medium was then collected, and the IL -2 concentration was measured by ELISA ( IL -2 immunoassay kit; R&D Systems, Minneapolis, MN ).
Statistical analysis was performed using Mann -Whitney analysis, and P < .05 was considered to be statistically significant. Cancer Gene Therapy ( Fig 1 ) . In this regard, the observed LacZ activity was 1.31Â10 5 RLU /mg protein for HSC2, 9.01Â10 4 RLU / mg protein for HSC3, and 1.64Â10 5 RLU /mg protein for OSC70. These data indicated that oral SSC cells were considerably less susceptible than HeLa to Adv -mediated gene transfer.
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Expression of CAR and integrins on oral SCC cell lines
We next investigated the biological basis of the relative resistance of oral SCC cell lines to Adv -mediated gene transfer. The expression of the primary adenovirus receptor, CAR, and the secondary adenovirus receptors, integrins a V b 3 and a V b 5 , were analyzed by flow cytometry in HeLa, HSC2, HSC3, and OSC70 cell lines. These studies demonstrated that the positive control HeLa cells clearly expressed CAR and both integrins. In contrast, the levels of CAR detected on the oral SCC cell lines were greatly reduced ( Fig 2 ) . Moreover, the a v b 5 integrin was expressed but the a v b 3 was not detected in oral SCC (Fig 2) . Because one of the secondary adenovirus receptors, integrin a V b 3 , was not detected in oral SCC, we examined other integrins -a 2 b 1 , a 3 b 1 -that were recognized by the RGD peptide motif. These studies demonstrated that both integrins were clearly expressed on all oral SCC cell lines ( Fig 2) . Thus, these data suggested that the relative CAR deficiency in oral SCC cells provided the principal explanation for the relative resistance of these cells to Advmediated transduction.
Improvement of transduction efficiency to oral SCC cell lines by F / RGD fiber -modified Adv
The CAR deficiency that was observed on the oral SCC cells suggests a requirement to bypass this receptor through CAR -independent pathways to achieve efficient gene delivery. To this end, we used genetically modified Adv carrying the RGD peptide sequence in the fiber domain and encoding the LacZ gene (AxCAZ3 -F /RGD ) for transduction of the human oral SCC cell lines. Direct comparison was done in these studies with the unmodified control virus 
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AxCAZ3 -F /wt. The application of AxCAZ3-F /RGD to HeLa cells resulted in a modest 1.2 -to 2.0 -fold augmentation of gene transfer efficacy compared with the control virus AxCAZ3 -F /wt (Fig 3Aa ) . We next tested AxCAZ3-F/ RGD on the human oral SCC cell lines. In contrast to HeLa, an augmentation in gene transfer was noted in these otherwise Ad -refractory cells. Specifically, the HSC2 ( Fig 3Ab ), HSC3 (Fig 3Ac ) , and OSC70 ( Fig 3Ad ) cells showed from 4.0 -to 5.3 -fold, from 5.6 -to 9.9 -fold, and from 4.4-to 6.3 -fold enhancements in gene transfer, respectively. These results demonstrated that F /RGD was able to augment adenovirus -mediated gene transfer to cells with low CAR expression, such as oral SCC.
Production of human IL -2 from oral SCC cell lines transduced with AxCAhIL2 -F / RGD
We attempted to apply the adenovirus Adv -F /RGD to gene therapy of oral cancer. We evaluated whether oral SCC cells infected with Ad -F/ RGD carrying the human IL -2 therapeutic gene (AxCAhIL2 -F /RGD ) produced a higher level of IL -2 than those infected with a vector containing control wild -type fiber ( AxCAhIL2-F/ wt ). IL -2 protein from IL -2-transfected cells of each of two oral SCC cell lines was assayed using an IL -2 ELISA kit. In HSC2 and HSC3, the level of IL -2 production after transduction with AxCAhIL2 -F /RGD was significantly ( P <.05) higher than that observed with AxCAhIL2-F/ wt at the same MOI (Fig 3B ) .
RGD insertion enhances Adv transduction efficiency in oral SCC in vivo
The in vivo environment might be markedly different from in vitro, and the transduction efficiency of Adv -F /RGD might be influenced by the intratumor environment, e.g., the intercellular adhesion -related extracellular matrix ( ECM ), which includes some integrin -binding molecules. Therefore, we employed a nude mouse HSC2 tumor xenograft model to evaluate the transduction efficiency of AxCAZ3 -F / RGD in vivo. As shown in Figure 4 , in controls, no bluestained areas were detected ( Fig 4A ) . In AxCAZ3 -F/ wtinjected tumor, positive blue -stained areas were weak and focally limited (Fig 4B ) . In contrast, use of AxCAZ3-F / RGD resulted in blue -stained areas spreading to most of the tumor ( Fig 4C ) . By microscopic observation, no positive blue cells were detected in the control tumor, either ( Fig  4D ) . In the AxCAZ3 -F /wt -injected tumor, blue -stained cells were found only at the thin layer at the circumference of the cancer nest ( Fig 4E ) . In AxCAZ3 -F /RGD -injected tumor, however, quite the opposite was found, with bluestained cells identified at the thick layer of the circumference of the cancer nest. However, even here, some unstained negative cells remained (Fig 4F ) . Tumors were treated with a single intratumoral injection of 7.5Â10 8 viral particles of AxCAZ3 -F / RGD, AxCAhIL2 -F / wt, or AxCAhIL2 -F / RGD. Tumor size was measured twice a week. Significant difference between AxCAhIL2 -F / RGD -treated group versus AxCAhIL2 -F / wt -treated group ( days 12 -27 ) or AxCAZ3 -F / RGDtreated group ( days 9 -36 ) ( P < .017 ). B: Histological analyses of sections of tumors in nude mice HSC2. Tumors were treated with AxCAZ3 -F / RGD ( a ), AxCAhIL2 -F / wt ( b ), and AxCAhIL2 -F / RGD ( c ). One week after treatment, sections from subcutaneous tumor were stained with hematoxylin and eosin ( original magnification: Â200 ).
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Treatment of the HSC2 xenograft model using AxCAhIL2 -F / RGD HSC2 xenografted tumors were treated with a single intratumoral injection of AxCAZ3 -F /RGD, AxCAhIL2-F /wt, or AxCAhIL2 -F /RGD at 7.5Â10 8 particles per virus ( n= 6 per group ). In the AxCAZ3 -F /RGD -injected control group, extensive tumor growth was observed ( Fig 5A ) . In the AxCAhIL2 -F /wt -treated group, aggressive tumors were still observed in 2/6 animals, but growth inhibition was seen in the remaining 4/6 animals. However, these tumors never regressed. In contrast, three regressed, two remained the same, and one grew in the AxCAhIL2-F/ RGD -treated group. Notably, AxCAhIL2 -F /RGD induced complete tumor regression in 3/6 animals, whereas none of the animals in the other virus -treated groups was cured. Recurrence was not seen in responders even 60 days after therapy in the AxCAhIL2 -F /RGD -treated group. The antitumoral effect of AxCAhIL2 -F /RGD was significantly greater than that of AxCAhIL2 -F /wt (P < .017, on days 12-27).
Next, we performed histopathological analysis by hematoxylin and eosin staining sections of subcutaneous tumors. In the control LacZ group, well -differentiated oral SCC but no necrotic areas were observed ( Fig 5Ba ) . In the AxCAhIL2 -F /wt -treated group, spotty necrotic areas with minimal infiltration of mononuclear cells were observed ( Fig 5Bb ) . In contrast, in the AxCAhIL2-F/ RGD -treated group, massive necrotic areas with infiltration of numerous mononuclear cells were observed (Fig 5Bc ) . Thus, inflammatory and immune responses were strongly induced in tumors treated with AxCAhIL2 -F /RGD, which led to the severe necrotic changes responsible for tumor regression.
Gene transfer to normal oral mucosa
We examined the Adv -F /RGD gene transduction on normal oral mucosal cells. Normal gingival mucosa and oral SCC cells were infected with AxCAZ3 -F /wt or AxCAZ3 -F / RGD at MOI of 3000 particles /cell. As shown in Figure 6 , A -C, X -gal -positive blue cells could not been detected among normal primary oral mucosal cells. In contrast, the transduction efficiency into oral SCC cells was 20% or 70% with AxCAZ3 -F /wt (Fig 6E ) or AxCAZ3 -F / RGD ( Fig 6F ) at the above MOI, respectively. Of further note, normal oral mucosa resisted adenoviral infection and, thus, these results suggest that AxCAZ3 -F /RGD has potential value as a therapeutic vector for oral SCC gene therapy.
Discussion
In this article, we have demonstrated that employment of Adv -F /RGD, carrying an RGD peptide motif in the fiber, can result in enhanced expression of an IL-2 transgene and 
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Modified adenovirus for oral cancer H Dehari et al improve in vivo antitumor effects against oral SCC expressing low levels of CAR. Ad initially binds to its target cell through the primary receptor, CAR. 18 Relative resistance to Advs has been reported to occur due to a deficiency of the cellular receptor. 15, 18 Furthermore, great variation in adenovirus receptor density was present among HNSCC cell lines. 17 Our study and another work 16 have demonstrated that the extreme resistance to adenoviral gene transfer in oral SCC cell lines was mainly associated with low expression of the primary adenovirus receptor CAR ( Figs 1 and 2) . To overcome this limitation, we attempted to accomplish gene delivery to these refractory tumor cells through a CARindependent pathway. As shown in Figures 3 and 4 , Adv -F/ RGD enhanced the efficiency of in vitro and in vivo gene delivery compared with Adv -F /wt. Our results agree with those reported previously, which demonstrated that the RGD -4C peptide at the HI loop of the fiber knob domain enabled the fiber mutant Adv to achieve gene transduction through binding of RGD to integrins. 16, 22 Nevertheless, in HeLa cells, the augmentation of transduction efficiency achieved by using Adv -F /RGD was low (Fig 3Aa ) . HeLa cells highly express both CAR and integrins ( Fig 2 ) . In the usual pathway of adenoviral infection, initially Ad attaches with high affinity to cell surface CAR through the viral fiber protein. Next, the adenovirus achieves internalization through interaction with integrins of the a V class. 29, 30 Even if Adv -F/ RGD bypasses the initial step, binding CAR through fiber protein with high -affinity Ad and modified Ad uses the same pathway to enter the target cell. Therefore, Adv -F /RGD may not efficiently further enhance gene transduction through binding of the RGD peptide to integrins on target cells, which already express sufficient CAR, such as HeLa cells. In addition, the RGD sequence has been suggested to recognize at least 12 of the integrin heterodimers. 31 ,32 Indeed, we found that in oral SCC cell lines, a 2 b 1 and a 3 b 1 integrins rather than a v b 3 and a v b 5 integrins were highly expressed (Fig 2 ) . Thus, the Adv -F /RGD vector achieved high transduction efficiency by recognizing integrins despite the fact that one of the secondary adenovirus receptors, a v b 3 integrin, was not expressed on oral SCC cell lines. Nevertheless, further studies are needed to clarify the relationship between integrin expression and Adv transduction efficiency.
It is known that intratumoral distribution of Adv -F /wt after direct injection is limited. 4, 33 Because oral SCC cells express many types of integrins, 34, 35 Adv -F /RGD recognizes those integrins and infects tumor cells. Furthermore, it is an advantage for adenovirus -mediated gene transduction that the interaction between Adv -F /RGD and a variety of integrins may extend the biological clearance time of Adv in the tumor. On the other hand, using Adv -F /wt, the distribution of Adv was similar to that of Adv -F /RGD. However, due to the deficiency of CAR, a 100% rate of infection of tumor cells by Adv -F /wt was not achieved. In fact, infection by Adv -F /wt was achieved only in the limited locality of the needle injection site, where a higher concentration of the Adv suspension was present.
According to microscopic observation as shown in Figure 4F , not all the tumor cells were infected even when highly efficient Adv -F/ RGD was used, and only the cells located in peripheral areas of the cancer nest were X -galpositive ( Fig 4F ) . An explanation for this phenomenon may reside in differences in localization and status of integrin expression, solidity of tumor, and characteristics of the ECM. It is conceivable that cytokine therapy such as IL -2 therapy may be an effective strategy to overcome these limitations.
In the present study, we have demonstrated that intratumoral injection of Adv -F /RGD resulted in a drastic antitumor effect as indicated by a marked increase in mononuclear cell infiltration and severe necrotic changes ( Fig 5Bc ) . In AxCAhIL2 -F /wt -injected tumors, in contrast, the spotty necrotic area was observed at cancer nests. As our in vivo experiments were carried out in an immunodeficient mouse xenograft model, the therapeutic effect cannot be mediated by specific T and B cells but must rely on NK cell -and macrophages -mediated antitumor effects. 36 In addition, there were no toxic side effects associated with adenoviral gene transfer under our experimental conditions (data not shown ). Our results suggest that an effective treatment strategy for tumors with low CAR expression, which resist adenovirus -mediated gene transfer, is to combine Adv -F /RGD and therapy relying on a bystander effect, such as IL -2 gene therapy.
We demonstrated that normal gingival mucosal cells are not susceptible to adenovirus infection with either Adv -F /wt or Adv -F /RGD ( Fig 6) . An explanation of this phenomenon could be that the expression of integrin subclasses is different in normal oral mucosal cells compared with oral SCC. Alternatively, oral mucosa may have a characteristic biological barrier such as presence of defensins, which are secreted by epithelial and oral mucosa and are reported to inhibit adenoviral infection. 37 Another possible explanation for the resistance of normal oral mucosa to adenovirus infection is that the cells were not of sufficient metabolic activity to support transgene expression. However, further studies are required to account for the resistance of normal oral mucosa to adenovirus infection. This finding -that oral mucosa resisted infection with either Adv -F /RGD or Adv -F /wt, although the former demonstrated hyperefficiency with tumor cells -is extremely encouraging regarding its use as a selective therapeutic vector.
In clinical trials, Adv -F /RGD may be very useful for gene therapy of human oral cancer. CAR expression by individual tumor cells in the same tumor varied greatly. 38 The situation in oral cancer may be similar. Especially in clinical cancer containing some cells with low CAR expression, Adv -F / RGD may take much higher transduction efficiency than Adv -F /wt. Furthermore, employing Adv -F /RGD and a conditional replication -competent Adv such as ONYX -015, 39 -42 which is now starting clinical trials in head and neck cancer and represents the most potent current gene therapy approach, may be even more effective. Recently, it was reported that fiber-modified replication-competent Adv possessed strong antitumor effects in vitro and in vivo. 43 In oral cancer therapy, local control is very important because death caused by distant metastasis is only 10-15%. Therefore, the development of novel gene therapy for local treatment of oral cancer would be extremely useful.
Currently, various adenovirus -mediated gene therapies for cancer, including oral cancer, are being examined. A simple approach to more effective clinical gene therapy is to use high -dose Adv, including repeated injection. A combination of different strategies, e.g., HSV-tk plus cytokine therapy, 4 is one potential approach to gene therapy for oral cancer. However, these suffer the potential disadvantage of increasing the side effects of Adv treatment. Exploiting the high transduction efficiency of Adv -F /RGD may reduce the Adv dose required and safely improve treatment outcome of oral cancer gene therapy.
